SAB4200779

Anti-NRAS (C-terminal) antibody produced in rabbit

IgG fraction of antiserum

• Sinónimos: GTPase NRas, Transforming protein N-Ras
• UNSPSC Code: 12352203
• NACRES: NA.41

Propiedades

• biological source: rabbit
• Quality Level: 200
• antibody form: IgG fraction of antiserum
• antibody product type: primary antibodies
• clone: polyclonal
• form: buffered aqueous solution
• mol wt: predicted mol wt ~21 kDa
• species reactivity: human
• enhanced validation: recombinant expression; Learn more about Antibody Enhanced Validation
• technique(s): immunoblotting: 1:2,000-1:4,000 using human HEK-293T cells over-expressing NRAS protein
• UniProt accession no.: P01111
• shipped in: dry ice
• storage temp.: −20°C
• target post-translational modification: unmodified
• Gene Information: human ... NRAS(4893)

Descripción

General description

Transforming protein N-Ras (NRAS), also known as GTPase NRas or Neuroblastoma RAS Viral (V-Ras) Oncogene Homolog, is a member of the Ras protein family and are low molecular-weight GTPases. NRAS is mapped to human chromosome location 1p13.2 and shows ubiquitous expression. Ras proteins have highly homologous primary amino acid sequence and differ in their C-terminal region termed as hypervariable region (HVR).

Specificity

Anti-NRAS (C-terminal) antibody specifically recognizes human NRAS and does not cross-react with HRAS or KRAS.

Immunogen

Synthetic peptide from the internal region of human NRAS protein, conjugated to KLH

Application

Anti-NRAS (C-terminal) antibody produced in rabbit has been used in immunoblotting.

Biochem/physiol Actions

Neuroblastoma RAS Viral (V-Ras) Oncogene Homolog (NRAS) was the first melanoma oncogene to be identified. Oncogenic NRAS mutations are single base substitutions (most commonly affecting residues G12, G13, or Q61) that lead to the stabilization of GTP binding and constitutive activation of RAS and downstream signaling cascades. Abnormal NRAS activity stimulates several signaling pathways, including mitogen-activated protein kinase (MAPK/ERK), serine/threonine-protein kinase (RAFs) (ARAF, BRAF, and CRAF), phosphatidylinositol 3-kinase (PI3K) and the RAS-like protein (RAL) guanine nucleotide exchange factors (GEFs) signaling pathways. This leads to uncontrolled cell proliferation, resistance to apoptosis and thus cancer therapy potential target. NRAS mutations are present in various cancers, including melanomas, acute myeloid leukemia, colon, thyroid and lung cancers. Mutations are also implicated in hematologic malignancies, including acute lymphocytic leukemia, myelodysplastic syndrome, multiple myeloma and chronic myelomonocytic leukemia.

Physical form

Solution in 0.01 M phosphate buffered saline, pH 7.4, containing 15 mM sodium azide.

Storage and Stability

For continuous use, store at 2–8 °C for up to one month. For extended storage, freeze in working aliquots. Repeated freezing and thawing is not recommended. If slight turbidity occurs upon prolonged storage, clarify the solution by centrifugation before use. Working dilution samples should be discarded if not used within 12 hours.

Disclaimer

Unless otherwise stated in our catalog, our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Información de seguridad

• Storage Class: 10 - Combustible liquids
• wgk_germany: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable